Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Price:
0.227 USD
-3.81%
Market Closed
Updated:
May 21, 2024
Sonoma Pharmaceuticals Inc
Total Liabilities & Equity
|
Sonoma Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Total Liabilities & Equity
$14.6m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
4%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Liabilities & Equity
$172B
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Liabilities & Equity
$99B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
23%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Liabilities & Equity
$221.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Liabilities & Equity
$105.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Liabilities & Equity
$63.9B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
See Also
What is Sonoma Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
14.6m
USD
14.6m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Total Liabilities & Equity amounts to 14.6m USD.
What is Sonoma Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
4%
4%
Over the last year, the Total Liabilities & Equity growth was 5%. The average annual Total Liabilities & Equity growth rates for Sonoma Pharmaceuticals Inc have been -7% over the past three years , -3% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet
